<DOC>
	<DOC>NCT00403416</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of AEB071 in preventing acute rejections after kidney transplantation, when combined with tacrolimus for the first 3 months and with myfortic thereafter.</brief_summary>
	<brief_title>Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criteria Male and female patients of any race 18 years or older Adult recipients of a kidney transplant from a deceased or from a living donor Recipients of a functioning Kidney:. Graft must be functional no later than 36h after transplantation. Exclusion criteria Need for medication prohibited by the protocol Patients or donors infected with hepatitis B or C, or with HIV. Patients with a history of cancer Patients with severe systemic infections Patients with heart diseases (own or family history) which are associated with an increased risk for arrhythmias. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>AEB071</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Mycophenolic acid</keyword>
	<keyword>Basiliximab</keyword>
	<keyword>Rejection</keyword>
	<keyword>Kidney function</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>